PDF DatasheetAntibody (Suitable for clinical applications)
| Specification | Recommendation |
|---|---|
| Recommended Dilution (Conc) | 1:25-1:50 |
| Pretreatment | EDTA Buffer pH 8.0 |
| Incubation Parameters | 30 min at Room Temperature |
Prior to use, inspect vial for the presence of any precipitate or other unusual physical properties. These can indicate that the antibody has degraded and is no longer suitable for patient samples. Please run positive and negative controls simultaneously with all patient samples to account and control for errors in laboratory procedure. Use of methods or materials not recommended by enQuire Bio including change to dilution range and detection system should be routinely validated by the user.
Cyclin D1 Information for Pathologists
Summary:
Cyclin D1 is also known as BCL1, B Cell Lymphoma #1, CCND1. Coded by BCL1 / PRAD1 (parathyroid adenoma 1) gene on #11q13. Responsible for transition to S phase by phosphorylating the retinoblastoma gene product, which releases transcription factors to initiate DNA replication. Overexpression promotes transformation to a malignant phenotype; overexpressed in many tumors. Cyclin D1 genotypes may be associated with nasopharyngeal carcinoma risk (Anticancer Res 2012;32:1093).
Common Uses By Pathologists:
Interpretation: nuclear stain. Mantle cell lymphoma: characterized by t(11;14) translocation, which places the cyclin D1 gene next to an immunoglobulin heavy chain enhancer gene; among lymphomas, cyclin D1 expression is very specific for mantle cell lymphoma; however, blastoid cases may be negative (Am J Surg Pathol 2012;36:214). Parathyroid: overexpressed in 40% of parathyroid adenomas, strong staining in carcinomas. Microscopic (histologic) images Images hosted on Pathout server:.
| Cyclin D1 General Information | |
|---|---|
| Alternate Names | |
| Molecular Weight | |
| 33.7 kDa | |
| Chromosomal Location | |
| q13.3 [chr: 11] [chr_start: 69641087] [chr_end: 69654474] [strand: 1] | |
| Curated Database and Bioinformatic Data | |
| Gene Symbol | CCND1 |
| Entrez Gene ID | 595 |
| RefSeq Protein Accession(s) | NP_444284 |
| RefSeq mRNA Accession(s) | NM_053056; |
| RefSeq Genomic Accession(s) | NC_000011; NG_007375 |
| UniProt ID(s) | P24385 |
| PharmGKB ID(s) | PA75 |
| KEGG Gene ID(s) | hsa:595 |
| Associated Diseases (KEGG IDs) | A chromosomal aberration involving CCND1 may be a cause of B-lymphocytic malignancy, particularly mantle-cell lymphoma (MCL). Translocation t(11;14)(q13;q32) with immunoglobulin gene regions. Activation of CCND1 may be oncogenic by directly altering progression through the cell cycle.; A chromosomal aberration involving CCND1 may be a cause of parathyroid adenomas. Translocation t(11;11)(q13;p15) with the parathyroid hormone (PTH) enhancer.; Multiple myeloma (MM) [MIM:254500]: A malignant tumor of plasma cells usually arising in the bone marrow and characterized by diffuse involvement of the skeletal system, hyperglobulinemia, Bence-Jones proteinuria and anemia. Complications of multiple myeloma are bone pain, hypercalcemia, renal failure and spinal cord compression. The aberrant antibodies that are produced lead to impaired humoral immunity and patients have a high prevalence of infection. Amyloidosis may develop in some patients. Multiple myeloma is part of a spectrum of diseases ranging from monoclonal gammopathy of unknown significance (MGUS) to plasma cell leukemia. {ECO:0000269|PubMed:8695815}. The gene represented in this entry is involved in disease pathogenesis. A chromosomal aberration involving CCND1 is found in multiple myeloma. Translocation t(11;14)(q13;q32) with the IgH locus. |
| General Description of Cyclin D1 . | |
| This antibody is specific to human cyclin D1. The cyclin D1 gene is located on 11q13 and has been shown to be amplified in a variety of tumors. Maximum expression of cyclin D1 occurs at a critical point in mid to late G1 phase of the cell cycle. | |
There are no reviews yet.